119864-31-2Relevant academic research and scientific papers
NEW DERIVATIVES OF EPIRUBICIN, THEIR MEDICINAL APPLICATION AND PHARMACEUTICALY ACCEPTABLE FORMS OF DRUGS
-
Page/Page column 10, (2008/06/13)
The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.
NEW DERIVATIVES OF EPIRUBICIN, THEIR MEDICINAL APPLICATION AND PHARMACEUTICALS ACCEPTABLE FORMS OF DRUGS
-
Page/Page column 5-6, (2010/11/27)
New derivatives of 7-O-(3'amino-2',3',6'-trideoxy-α,β,L- arabinoheksopiranosyl)-adriamycinone (epirubicin) presented at Formula 1, where R1, R2, R3 and R4 are the same and indicate hydrogen atom, alkyl group, isopropyl, alkenyl or alkinyl, especially acetyl or alkylcarbonyl group, all with alkyl chain containing 1 to 5 carbon atoms or dimethylformamidinyl group, at which if R1 and R4 indicate simultaneously hydrogen atom, then R3 indicates dimethylformamidinyl group. According to the invention, medical application of novel epirubicin derivatives is characterized by the fact, that derivatives presented at Formula 1 are used as active substances potently inhibiting hepatitis C virus (HCV) replication. Pharmaceutically acceptable form of the drug against hepatitis C virus (HCV) infections as active substance contains epirubicin derivatives presented at Formula (1), where R1, R2, R3 and R4 have above mentioned indications, eventually in the form of hydrochloride. According to invention, form of the drug ensures simultaneously low toxicity in Huh 7 and PBMC cells, therapeutic index (TI) better than for epirubicin, and lower than for epirubicin acute toxicity in vivo.
